Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo a Comparar JNJ-79635322 e Teclistamab em Participantes com Mieloma Múltiplo Recorrente ou Refratário (TRIlogy-5)

24 de setembro de 2026 atualizado por: Janssen Research & Development, LLC

Um Estudo Randomizado de Fase 3 a Comparar JNJ-79635322 Versus Teclistamab em Participantes com Mieloma Múltiplo Recorrente ou Refratário Após 1 a 3 Linhas de Terapia Prévia, Incluindo um Anticorpo Anti-CD38 e Lenalidomida

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

700

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

  • Alemanha
      • Freiburg im Breisgau, Alemanha, 79106
        • Recrutamento
        • Universitaetsklinikum Freiburg
      • Hamburg, Alemanha, 22763
        • Recrutamento
        • Asklepios Klinik Altona
      • Hamburg, Alemanha, 20251
        • Recrutamento
        • Universitaetsklinikum Hamburg Eppendorf
      • Tübingen, Alemanha, 72076
        • Recrutamento
        • Universitaetsklinik Tuebingen
  • Austrália
      • Darlinghurst, Austrália, 2010
        • Recrutamento
        • St Vincent s Hospital Sydney
      • Garran, Austrália, 2605
        • Recrutamento
        • Canberra Hospital
      • Heidelberg, Austrália, 3084
        • Recrutamento
        • Austin Hospital
      • Macquarie University, Austrália, 2109
        • Recrutamento
        • Macquarie University Hospital
      • Melbourne, Austrália, 3128
        • Recrutamento
        • Box Hill Hospital
      • Perth, Austrália, 6000
        • Recrutamento
        • Royal Perth Hospital
      • Port Macquarie, Austrália, 2444
        • Recrutamento
        • Port Macquarie Base Hospital
  • Brasil
      • Brasília, Brasil, 70200 730
        • Recrutamento
        • Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia
      • Curitiba, Brasil, 81520-060
        • Recrutamento
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Florianópolis, Brasil, 88020 210
        • Recrutamento
        • Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
      • Joinville, Brasil, 89201-260
        • Recrutamento
        • Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
      • Porto Alegre, Brasil, 90050 170
        • Recrutamento
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Rio de Janeiro, Brasil, 22775-002
        • Recrutamento
        • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
      • São José do Rio Preto, Brasil, 15090-000
        • Recrutamento
        • Funfarme Sjrp
      • São Paulo, Brasil, 01323 001
        • Recrutamento
        • Real e Benemerita Associacao Portuguesa de Beneficencia
      • São Paulo, Brasil, 05651 901
        • Recrutamento
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasil, 04537 081
        • Recrutamento
        • Clinica Medica Sao Germano LTDA
  • Canadá
    • Alberta
      • Calgary, Alberta, Canadá, T2N 5G2
        • Recrutamento
        • Arthur J E Child Comprehensive Cancer Centre
      • Edmonton, Alberta, Canadá, T6G 1Z2
        • Recrutamento
        • Cross Cancer Institute
    • Ontario
      • Oshawa, Ontario, Canadá, L1G-2B9
        • Recrutamento
        • Lakeridge Health Oshawa
      • Toronto, Ontario, Canadá, M5G 2M9
        • Recrutamento
        • Princess Margaret Hospital
  • China
      • Beijing, China, 100034
        • Recrutamento
        • Peking University First Hospital
      • Beijing, China, 100006
        • Recrutamento
        • Peking Union Medical College Hospital
      • Changchun, China, 130061
        • Recrutamento
        • The First Hospital of Jilin University
      • Chaoyang District, China, 100020
        • Recrutamento
        • Beijing Chaoyang Hospital
      • Chengdu, China, 610072
        • Recrutamento
        • Sichuan Academy of Medical Science Sichuan Provincial Peoples Hospital
      • Guangzhou, China, 510710
        • Recrutamento
        • Sun Yat Sen University Cancer Center
      • Hangzhou, China, 310003
        • Recrutamento
        • The First Affiliated Hospital Zhejiang University College of Medicine
      • Nanchang, China, 330006
        • Recrutamento
        • The First Affiliated Hospital of NanChang University
      • Nanjing, China, 210008
        • Recrutamento
        • Nanjing Drum Tower Hospital
      • Shanghai, China, 200434
        • Recrutamento
        • Shanghai Fourth People s Hospital
      • Shenzhen, China, 518036
        • Recrutamento
        • Peking University Shenzhen Hospital
      • Tianjin, China, 300060
        • Recrutamento
        • Tianjin Medical University Cancer Institute and Hospital
      • Tijian, China, 300020
        • Recrutamento
        • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
      • Wenzhou, China, 325000
        • Recrutamento
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, China, 430032
        • Recrutamento
        • Wuhan Tongji Hospital Tongji Medical College
      • Xi'an, China, 710004
        • Recrutamento
        • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Coréia do Sul
      • Goyang-si, Coréia do Sul, 10408
        • Recrutamento
        • National Cancer Center
      • Gyeonggi-do, Coréia do Sul, 13620
        • Recrutamento
        • Seoul National University Bundang Hospital
      • Hwasun, Coréia do Sul, 58128
        • Recrutamento
        • Chonnam National University Hwasun Hospital
      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital
      • Seoul, Coréia do Sul, 06351
        • Recrutamento
        • Samsung Medical Center
      • Seoul, Coréia do Sul, 06591
        • Recrutamento
        • The Catholic University of Korea Seoul St Marys Hospital
  • Espanha
      • Barcelona, Espanha, 08036
        • Recrutamento
        • Hosp. Clinic de Barcelona
      • Barcelona, Espanha, 08035
        • Recrutamento
        • Hosp Univ Vall D Hebron
      • Cáceres, Espanha, 10003
        • Recrutamento
        • Hosp. San Pedro de Alcantara
      • Córdoba, Espanha, 14004
        • Recrutamento
        • Hosp Reina Sofia
      • Jerez de la Frontera, Espanha, 11407
        • Recrutamento
        • Hosp. de Jerez de La Frontera
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hosp. Univ. 12 de Octubre
      • Pamplona, Espanha, 31008
        • Recrutamento
        • Clinica Univ. de Navarra
      • Salamanca, Espanha, 37007
        • Recrutamento
        • Hosp Clinico Univ de Salamanca
      • Santander, Espanha, 39008
        • Recrutamento
        • Hosp. Univ. Marques de Valdecilla
      • Santiago de Compostela, Espanha, 15706
        • Recrutamento
        • Hosp. Clinico Univ. de Santiago
      • Seville, Espanha, 41013
        • Recrutamento
        • Hosp. Virgen Del Rocio
  • Estados Unidos
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35211
        • Recrutamento
        • Alabama Oncology
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85054
        • Recrutamento
        • Mayo Clinic 1
    • Arkansas
      • Springdale, Arkansas, Estados Unidos, 72762
        • Recrutamento
        • Highlands Oncology Group
    • California
      • Beverly Hills, California, Estados Unidos, 90211
        • Recrutamento
        • Beverly Hills Cancer Center Clinical Research Advisors LLC
      • Irvine, California, Estados Unidos, 92612
        • Recrutamento
        • UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Los Angeles, California, Estados Unidos, 90067
        • Recrutamento
        • Valkyrie Clinical Trials
      • Orange, California, Estados Unidos, 92868
        • Recrutamento
        • University of California Irvine Medical Center
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Recrutamento
        • Colorado Blood Cancer Institute
    • Connecticut
      • Farmington, Connecticut, Estados Unidos, 06030
        • Recrutamento
        • University of Connecticut Health Center
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Recrutamento
        • Mayo Clinic Jacksonville
      • Pembroke Pines, Florida, Estados Unidos, 33026
        • Recrutamento
        • Memorial Cancer Institute
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60607
        • Recrutamento
        • Rush University System for Health
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46237-8601
        • Recrutamento
        • Franciscan Health
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • Recrutamento
        • University of Iowa Hospitals and Clinics
      • Waukee, Iowa, Estados Unidos, 50263
        • Recrutamento
        • Mission Cancer Blood University of Iowa Health Care
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40207
        • Recrutamento
        • Norton Cancer Institute
    • Louisiana
      • Shreveport, Louisiana, Estados Unidos, 71103
        • Recrutamento
        • LSU Health Feist Weiller Cancer Center
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Recrutamento
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02111
        • Recrutamento
        • Tufts Medical Center
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Recrutamento
        • Karmanos Cancer Institute
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • Recrutamento
        • University Of Minnesota Medical Center
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68130
        • Recrutamento
        • Nebraska Cancer Specialists
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816
        • Recrutamento
        • Astera Cancer Care
    • New Mexico
      • Santa Fe, New Mexico, Estados Unidos, 87505
        • Recrutamento
        • Christus St. Vincent Regional Cancer Center
    • New York
      • Albany, New York, Estados Unidos, 12208
        • Recrutamento
        • New York Oncology Hematology
      • Mineola, New York, Estados Unidos, 11501
        • Recrutamento
        • Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
      • New York, New York, Estados Unidos, 10016
        • Recrutamento
        • NYU Langone Health Manhattan
      • Shirley, New York, Estados Unidos, 11967
        • Recrutamento
        • New York Cancer and Blood Specialists
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27705
        • Recrutamento
        • Duke University Medical Center
    • Ohio
      • Canton, Ohio, Estados Unidos, 44718
        • Recrutamento
        • Gabrail Cancer Center
      • Cincinnati, Ohio, Estados Unidos, 45069
        • Recrutamento
        • The Christ Hospital
      • Dayton, Ohio, Estados Unidos, 45415
        • Recrutamento
        • Dayton Physicians Network Urology
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97401
        • Recrutamento
        • Willamette Valley Cancer Institute and Research Center
    • South Carolina
      • Greenville, South Carolina, Estados Unidos, 29607
        • Recrutamento
        • Bon Secours Saint Francis Cancer Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • Tennessee Oncology, PLLC
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Recrutamento
        • Baylor University Medical Center
      • Lubbock, Texas, Estados Unidos, 79410
        • Recrutamento
        • Joe Arrington Cancer Research Treatment Center
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84102
        • Recrutamento
        • Utah Cancer Specialists
    • Washington
      • Tacoma, Washington, Estados Unidos, 98405
        • Recrutamento
        • NorthWest Medical Specialties, PLLC
  • França
      • Amiens, França, 80000
        • Recrutamento
        • CHU Amiens
      • Lyon, França, 69002
        • Recrutamento
        • Hospices Civils de Lyon HCL
      • Montpellier, França, 34295
        • Recrutamento
        • CHRU Montpellier - Hopital Saint-Eloi
      • Nantes, França, 44000
        • Recrutamento
        • CHU Nantes - Hotel Dieu
      • Poitiers, França, 86021
        • Recrutamento
        • CHU Poitiers - Hopital la Miletrie
      • Talence, França, 33400
        • Recrutamento
        • CHU Bordeaux
      • Toulouse, França, 31300
        • Recrutamento
        • CHU Toulouse
      • Tours, França, 37000
        • Recrutamento
        • CHRU de Tours
  • Grécia
      • Athens, Grécia, 11528
        • Recrutamento
        • Alexandra General Hospital of Athens
      • Athens, Grécia, 106 76
        • Recrutamento
        • Evangelismos S A
      • Athens, Grécia, 124 62
        • Recrutamento
        • University General Hospital Attikon General Hospital Of West Attica H Agia Varvara
      • Ioannina, Grécia, 455 00Q
        • Recrutamento
        • University General Hospital of Ioannina
  • Israel
      • Ashdod, Israel, 7747629
        • Recrutamento
        • Samson Assuta Ashdod University Hospital
      • Haifa, Israel, 3436212
        • Recrutamento
        • Carmel Medical Center
      • Haifa, Israel, 3109601
        • Recrutamento
        • Rambam Med.Center - Hematology Institute
      • Petah Tikva, Israel, 4941492
        • Recrutamento
        • Rabin Medical Center
      • Ramat Gan, Israel, 5266202
        • Recrutamento
        • Sheba Medical Center
      • Tel Aviv, Israel, 6423906
        • Recrutamento
        • Tel Aviv Sourasky Medical Center
  • Itália
      • Bari, Itália, 70124
        • Recrutamento
        • IRCCS Istituto Tumori Giovanni Paolo II
      • Bologna, Itália, 40138
        • Recrutamento
        • A O U Sant Orsola Malpighi
      • Bolzano, Itália, 39100
        • Recrutamento
        • Azienda Sanitaria dell'Alto Adige - Ospedale di Bolzano
      • Milan, Itália, 20132
        • Recrutamento
        • Ospedale San Raffaele di Milano
      • Milan, Itália, 20153
        • Recrutamento
        • ASST Santi Paolo e Carlo
      • Novara, Itália, 28100
        • Recrutamento
        • Azienda Ospedaliero Universitaria Maggiore della Carita di Novara
      • Palermo, Itália, 90146
        • Recrutamento
        • Casa di Cura La Maddalena
      • Pescara, Itália, 65124
        • Recrutamento
        • Ospedale S. Spirito, Azienda Sanitaria Pescara
      • Rimini, Itália, 47900
        • Recrutamento
        • Ospedale Infermi Rimini
      • Varese, Itália, 21100
        • Recrutamento
        • ASST dei Sette Laghi, Ospedale di Circolo e Fonazione Macchi
  • Japão
      • Chiba, Japão, 260-8717
        • Recrutamento
        • Chiba Cancer Center
      • Fukuoka, Japão, 810 8563
        • Recrutamento
        • National Hospital Organization Kyushu Medical Center
      • Gunma, Japão, 371-0034
        • Recrutamento
        • Gunma University Hospital
      • Kamakura-shi, Japão, 247-8533
        • Recrutamento
        • Shonan Kamakura General Hospital
      • Kyoto, Japão, 602-8566
        • Recrutamento
        • University Hospital Kyoto Prefectural University of Medicine
      • Matsuyama, Japão, 790-8524
        • Recrutamento
        • Matsuyama Red Cross Hospital
      • Okayama, Japão, 701-1192
        • Recrutamento
        • National Hospital Organization Okayama Medical Center
      • Sapporo, Japão, 060-8604
        • Recrutamento
        • Sapporo City General Hospital
      • Tokyo, Japão, 135-8550
        • Recrutamento
        • The Cancer Institute Hospital of JFCR
      • Yokohama, Japão, 241 8515
        • Recrutamento
        • Kanagawa Cancer Center
  • Polônia
      • Bydgoszcz, Polônia, 85 168
        • Recrutamento
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
      • Gdansk, Polônia, 80 214
        • Recrutamento
        • Uniwersyteckie Centrum Kliniczne
      • Katowice, Polônia, 40 519
        • Recrutamento
        • Pratia Onkologia Katowice
      • Lublin, Polônia, 20 090
        • Recrutamento
        • Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
      • Warsaw, Polônia, 02-172
        • Recrutamento
        • MTZ Clinical Research Powered by Pratia
      • Wałbrzych, Polônia, 58 309
        • Recrutamento
        • Specjalistyczny Szpital im dra Alfreda Sokolowskiego w Walbrzychu
  • Taiwan
      • Kaohsiung City, Taiwan, 833
        • Recrutamento
        • Chang Kung Memorial Hospital
      • Taichung, Taiwan, 40705
        • Recrutamento
        • Taichung Veterans General Hospital
      • Taichung, Taiwan, 40447
        • Recrutamento
        • China Medical University Hospital
      • Tainan, Taiwan, 70403
        • Recrutamento
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 100
        • Recrutamento
        • National Taiwan University Hospital
      • Taipei, Taiwan, 112
        • Recrutamento
        • Taipei Veterans General Hospital
  • Tcheca
      • Brno, Tcheca, 625 00
        • Recrutamento
        • Fakultni nemocnice Brno
      • Hradec Králové, Tcheca, 500 05
        • Recrutamento
        • FN Hradec Kralove
      • Ostrava, Tcheca, 708 52
        • Recrutamento
        • Fakultni Nemocnice Ostrava
      • Plzen-Lochotin, Tcheca, 323 00
        • Recrutamento
        • FN Plzen
      • Prague, Tcheca, 128 08
        • Recrutamento
        • VFN Praha
  • Turquia (Türkiye)
      • Ankara, Turquia (Türkiye), 06680
        • Recrutamento
        • Liv Hospital Ankara
      • Ankara, Turquia (Türkiye), 06010
        • Recrutamento
        • Gulhane Egitim ve Arastirma Hastanesi
      • Ankara, Turquia (Türkiye), 06200
        • Recrutamento
        • Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
      • Ankara, Turquia (Türkiye), 06620
        • Recrutamento
        • Ankara University Medical Faculty
      • Ankara, Turquia (Türkiye), 6170
        • Recrutamento
        • Ankara Etlik Sehir Hastanesi
      • Antalya, Turquia (Türkiye), 07025
        • Recrutamento
        • Memorial Antalya Hospital
      • Istanbul, Turquia (Türkiye), 34214
        • Recrutamento
        • Medipol Mega University Hospital
      • Istanbul, Turquia (Türkiye), 34381
        • Recrutamento
        • Istanbul Florance Nightingale Hospital
      • Izmir, Turquia (Türkiye), 35001
        • Recrutamento
        • Izmir Tinaztepe University Galen Hospital
      • Mersin, Turquia (Türkiye), 33110
        • Recrutamento
        • Mersin University Medical Faculty
      • Samsun, Turquia (Türkiye), 55420
        • Recrutamento
        • Ondokuz Mayis University
  • Índia
      • Bengaluru, Índia, 560054
        • Recrutamento
        • M S Ramaiah Medical College and Hospital
      • Gūrgaon, Índia, 122002
        • Recrutamento
        • Fortis Memorial Research Institute
      • Jaipur, Índia, 302017
        • Recrutamento
        • Bhagwan Mahaveer Cancer Hospital & Research Centre
      • Kolkata, Índia, 700156
        • Recrutamento
        • Tata Medical Center
      • Kolkata, Índia, 700014
        • Recrutamento
        • Nil Ratan Sircar Medical College and Hospital
      • New Delhi, Índia, 110085
        • Recrutamento
        • Rajiv Gandhi Cancer Institute and Research Centre
      • Pune, Índia, 411004
        • Recrutamento
        • Deenanath Mangeshkar Hospital and Research Centre

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion criteria:

  • Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory
  • Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication
  • Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment

Exclusion criteria:

  • Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
  • Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients
  • Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM
  • Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A: JNJ-79635322

Participants will receive subcutaneous (SC) dose of JNJ-79635322 treatment of a finite duration or intolerable toxicity (whichever is first).
Medicamento: JNJ-79635322

JNJ-79635322 will be administered as SC injection.
Comparador Ativo: Arm B: Teclistamab

Participants will receive teclistamab as a SC injection until PD or intolerable toxicity.
Medicamento: Teclistamab

Teclistamab will be administered as SC injection.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Complete Response (CR) or Better
Prazo: Up to approximately 41 months

CR or better is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to subsequent antimyeloma therapy in accordance with the international myeloma working group (IMWG) criteria during or after the study treatment.
Up to approximately 41 months
Progression-Free Survival (PFS)
Prazo: Up to approximately 41 months

PFS is defined as the duration from the date of randomization to either progressive disease (PD) or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.
Up to approximately 41 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall Response Rate (ORR)
Prazo: Up to approximately 41 months

ORR is defined as the percentage of participants who achieve partial response (PR) or better prior to subsequent antimyeloma therapy in accordance with the IMWG criteria.
Up to approximately 41 months
Very Good Partial Response (VGPR) or Better
Prazo: Up to approximately 41 months

VGPR or better is defined as the percentage of participants achieving VGPR, CR, or sCR prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment.
Up to approximately 41 months
Duration of Response (DoR)
Prazo: Up to approximately 41 months

DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG response criteria or death due to any cause, whichever occurs first.
Up to approximately 41 months
Minimal Residual Disease (MRD)-negative CR
Prazo: Up to approximately 41 months

MRD-negative CR is defined as the percentage of participants with CR or better who achieve MRD-negative status, as determined by next-generation flow cytometry (NGF), at any time point after randomization and prior to PD or subsequent antimyeloma therapy.
Up to approximately 41 months
MRD-negative CR at 1 Year
Prazo: At 1 Year

MRD-negative CR at 1 year is defined as the percentage of participants who achieve MRD-negative status at 12 months as determined by NGF, prior to PD or subsequent antimyeloma therapy and who also achieve CR or better according to IMWG criteria.
At 1 Year
MRD-negative CR at 5 Years
Prazo: At 5 Years

MRD-negative CR at 5 years is defined as the percentage of participants who achieve MRD-negative status at 5 years as determined by NGF, prior to PD or subsequent antimyeloma therapy and who also achieve CR or better according to IMWG criteria.
At 5 Years
Progression-Free Survival on the First Subsequent Line of Antimyeloma Therapy (PFS2)
Prazo: Up to approximately 41 months

PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. Those who are alive and for whom a second disease progression has not been observed are censored at the last date of follow-up.
Up to approximately 41 months
Overall Survival (OS)
Prazo: Up to approximately 41 months

OS is defined as the time from the date of randomization to the date of the participant's death due to any cause.
Up to approximately 41 months
Time To Next Line of Therapy (TTNT)
Prazo: Up to approximately 41 months

TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event.
Up to approximately 41 months
Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Prazo: Up to approximately 41 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent anticancer therapy will be considered treatment-related regardless of the start date of the event. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.
Up to approximately 41 months
Number of Participants with Abnormalities in Laboratory Parameters
Prazo: Up to approximately 41 months

Number of participants with abnormalities in laboratory parameters (serum chemistry, hematology, and urinalysis) will be reported.
Up to approximately 41 months
Change from Baseline in Health-related Quality of Life (HRQoL), Symptoms and Functioning using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Scores
Prazo: From Baseline up to approximately 41 months

Change from baseline in HRQoL, symptoms and functioning as assessed by MySIm-Q score will be reported. The MySIm-Q is a disease-specific patient-reported outcome (PRO) assessment with established content validity for participants with relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM.
From Baseline up to approximately 41 months
Change from Baseline in HRQoL, Symptoms and Functioning Using the European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Scores
Prazo: From Baseline up to approximately 41 months

Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 score will be reported.
From Baseline up to approximately 41 months
Change from Baseline in HRQoL, Symptoms and Functioning Using the European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Scores
Prazo: From Baseline up to approximately 41 months

The EQ-5D-5L is a generic measure of health status that contains 5-item questionnaire that assesses 5 domains (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 dimensions are used to compute a single utility score, ranging from zero (0.0) to 1 (1.0), representing the general health status of the individual.
From Baseline up to approximately 41 months
Time to Worsening in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores
Prazo: Up to approximately 41 months

Time to worsening in HRQoL, symptoms and functioning using the MySIm-Q scale scores will be reported. The MySIm-Q is a disease-specific patient-reported outcome (PRO) assessment with established content validity for participants with RRMM and newly diagnosed MM.
Up to approximately 41 months
Time to Worsening in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores
Prazo: Up to approximately 41 months

Time to worsening in HRQoL, symptoms and functioning using the EORTC-QLQ-C30 score will be reported.
Up to approximately 41 months
Time to Worsening in HRQoL, Symptoms and Functioning using the EQ-5D-5L Scale Scores
Prazo: Up to approximately 41 months

The EQ-5D-5L is a generic measure of health status that contains 5-item questionnaire that assesses 5 domains (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 dimensions are used to compute a single utility score, ranging from zero (0.0) to 1 (1.0), representing the general health status of the individual.
Up to approximately 41 months
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores
Prazo: Up to approximately 41 months

The MySIm-Q is a disease-specific PRO assessment with established content validity for participants with RRMM and newly diagnosed MM.
Up to approximately 41 months
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores
Prazo: Up to approximately 41 months

Percentage of participants with meaningful improvement in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 score will be reported.
Up to approximately 41 months
Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores
Prazo: Up to approximately 41 months

The EQ-5D-5L is a generic measure of health status that contains 5-item questionnaire that assesses 5 domains (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 dimensions are used to compute a single utility score, ranging from zero (0.0) to 1 (1.0), representing the general health status of the individual.
Up to approximately 41 months
Percentage of Participants who Report Side Effects Burden on the European Organization for Research and Treatment of Cancer Item List (EORTC IL) 46
Prazo: Up to approximately 41 months

The EORTC IL46 consists of one single question that measures global impression of burden due to treatment-related symptoms. The response options range from "not at all" to "very much" on a 4-point scale.
Up to approximately 41 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Janssen Research & Development, LLC

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de maio de 2026

Conclusão Primária (Estimado)

29 de abril de 2029

Conclusão do estudo (Estimado)

8 de dezembro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

1 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de abril de 2026

Primeira postagem (Real)

8 de abril de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 79635322MMY3002

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever